ADMA concentration changes across the menstrual cycle and during oral contraceptive use: The Cardiovascular Risk in Young Finns Study

European Journal of Endocrinology

Volumn 162, Issue 2, 2010, Pages 259-265

  Valtonen, Pirjo ^a   Punnonen, Kari ^a   Saarelainen, Heli ^a   Heiskanen, Nonna ^a   Raitakari, Olli T ^b   Juonala, Markus ^b   Viikari, Jorma S A ^b   Alfthan, Georg ^c   Kähönen, Mika ^d   Laaksonen, Reijo ^e   Lyyra Laitinen, Tiina ^a   Laitinen, Tomi ^a   Heinonen, Seppo ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

^e TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ARGININE DERIVATIVE; C REACTIVE PROTEIN; CREATININE; DIMETHYLARGININE; ESTROGEN; GESTAGEN; N(G),N(G) DIMETHYLARGININE; ORAL CONTRACEPTIVE AGENT; UNCLASSIFIED DRUG;

ADULT; ARTERY DIAMETER; ARTICLE; BRACHIAL ARTERY; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; FEMALE; FINLAND; FOLLICULAR PHASE; HUMAN; LUTEAL PHASE; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; ORAL CONTRACEPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; ARGININE; ATHEROSCLEROSIS; BRACHIAL ARTERY; C-REACTIVE PROTEIN; CONTRACEPTIVES, ORAL; CREATININE; ESTROGENS; FEMALE; FINLAND; HUMANS; MENSTRUAL CYCLE; PROGESTERONE CONGENERS; PROSPECTIVE STUDIES; RISK FACTORS; VASODILATION; YOUNG ADULT;

EID: 75149152019     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-0658     Document Type: Article

References (35)

1. Mendelsohn ME. Protective effects of estrogen on the cardiovascular system. American Journal of Cardiology 2002 89 12E-17E (discussion 17E-18E).
2. Cevik D, Unay O, Durmusoglu F, Yurdun T & Bilsel AS. Plasma markers of NO synthase activity in women after ovarian hyperstimulation: influence of estradiol on ADMA. Vascular Medicine 2006 11 7-12.
3. Ardigo D, Stuehlinger M, Franzini L, Valtuena S, Piatti PM, Pachinger O, Reaven GM & Zavaroni I. ADMA is independently related to flow-mediated vasodilation in subjects at low cardiovascular risk. European Journal of Clinical Investigation 2007 37 263-269.
4. Juonala M, Viikari JS, Alfthan G, Marniemi J, Kähönen M, Taittonen L, Laitinen T & Raitakari OT. Brachial artery flow-mediated dilation and asymmetrical dimethylarginine in the Cardiovascular Risk in Young Finns Study. Circulation 2007 116 1367-1373.
5. Vallance P. Importance of asymmetrical dimethylarginine in cardiovascular risk. Lancet 2001 358 2096-2097.
6. Valkonen VP, Päivä H, Salonen JT, Lakka TA, Lehtimäki T, Laakso J & Laaksonen R. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001 358 2127-2128.
7. Cooke JP. NO and angiogenesis. Atherosclerosis 2003 4 53-60.
8. Zoccali C, Bode-Böger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frölich J & Böger R. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001 358 2113-2117.
9. Ozgurtas T, Oktenli C, Dede M, Tapan S, Kenar L, Sanisoglu SY, Yesilova Z, Yenen MC, Erbil MK & Baser I. Metformin and oral contraceptive treatments reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS). Atherosclerosis 2008 200 336-344.
10. Savvidou MD, Hingorani AD, Tsikas D, Frölich JC, Vallance P & Nicolaides KH. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet 2003 361 1511-1517.
11. Beltowski J & Kedra A. Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy. Pharmacological Reports 2006 58 159-178.
12. Wahbi N, Dalton RN, Turner C, Denton M, Abbs I & Swaminathan R. Dimethylarginines in chronic renal failure. Journal of Clinical Pathology 2001 54 470-473.
13. Verhoeven MO, Hemelaar M, Teerlink T, Kenemans P & van der Mooren MJ. Effects of intranasal versus oral hormone therapy on asymmetric dimethylarginine in healthy postmenopausal women: a randomized study. Atherosclerosis 2007 195 181-188.
14. Post MS, Verhoeven MO, van der Mooren MJ, Kenemans P, Stehouwer CD & Teerlink T. Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebo-controlled 12-week study in healthy early postmenopausal women. Journal of Clinical Endocrinology and Metabolism 2003 88 4221-4226.
15. Teerlink T, Neele SJ, de Jong S, Netelenbos JC & Stehouwer CD. Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women. Clinical Science 2003 105 67-71.
16. Valtonen P, Laitinen T, Lyyra-Laitinen T, Raitakari OT, Juonala M, Viikari JSA, Heiskanen N, Vanninen E, Punnonen K & Heinonen S. Serum L-homoarginine concentration is elevated during normal pregnancy and is related to flow-mediated vasodilatation. Circulation Journal 2008 72 1879-1884.
17. Holden DP, Fickling SA, Whitley GS & Nussey SS. Plasma concentrations of asymmetric dimethylarginine, a natural inhibitor of nitric oxide synthase, in normal pregnancy and preeclampsia. American Journal of Obstetrics and Gynecology 1998 178 551-556.
18. Raitakari OT, Juonala M, Rönnemaa T, Keltikangas-Järvinen L, Räsänen L, Pietikäinen M, Hutri-Kähönen N, Taittonen L, Jokinen E, Marniemi J, Jula A, Telama R, Kähönen M, Lehtimäki T, Åkerblom HK & Viikari JSA. Cohort Profile: the Cardiovascular Risk in Young Finns Study. International Journal of Epidemiology 2008 37 1220-1226.
19. Juonala M, Viikari JS, Hutri-Kähönen N, Pietikäinen M, Jokinen E, Taittonen L, Marniemi J, Rönnemaa T & Raitakari OT. The 21-year follow-up of the Cardiovascular Risk in Young Finns Study: risk factor levels, secular trends and east-west difference. Journal of Internal Medicine 2004 255 457-468.
20. Teerlink T, Nijveldt RJ, de Jong S & van Leeuwen PA. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Analytical Biochemistry 2002 303 131-137.
21. Cockcroft DW & Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976 16 31-41.
22. Giusti M, Fazzuoli L, Cavallero D & Valenti S. Circulating nitric oxide changes throughout the menstrual cycle in healthy women and women affected by pathological hyperprolactinemia on dopamine agonist therapy. Gynecological Endocrinology 2002 16 407-412.
23. Teran E, Escudero C & Vivero S. Physiological changes in platelet aggregation and nitric oxide levels during menstrual cycle in healthy women. Nitric Oxide 2002 7 217-222.
24. Verhoeven MO, Hemelaar M, van der Mooren MJ, Kenemans P & Teerlink T. Oral, more than transdermal, oestrogen therapy lowers asymmetric dimethylarginine in healthy postmenopausal women: a randomized, placebo-controlled study. Journal of Internal Medicine 2006 259 199-208.
25. Holden DP, Cartwright JE, Nussey SS & Whitley GS. Estrogen stimulates dimethylarginine dimethylaminohydrolase activity and the metabolism of asymmetric dimethylarginine. Circulation 2003 108 1575-1580.
26. Bunck MC, Giltay EJ, Diamant M, Gooren LJ & Teerlink T. Differential effects of cross-sex hormonal treatment on plasma asymmetric dimethylarginine (ADMA) in healthy male-to-female and female-to-male transsexuals. Atherosclerosis 2009 206 245-250.
27. Kilic S, Yilmaz N, Erdogan G, Aydin M, Tasdemir N, Doganay M & Batioglu S. Effect of non-oral estrogen on risk markers for metabolic syndrome in early surgically menopausal women. Climacteric 2009 DOI: 10.1080/13697130902914650.
28. Wander K, Brindle E & O'Connor KA. C-reactive protein across the menstrual cycle. American Journal of Physical Anthropology 2008 136 138-146.
29. Raitakari M, Mansikkaniemi K, Marniemi J, Viikari JSA & Raitakari OT. Distribution and determinants of serum high-sensitive C-reactive protein in a population of young adults. The Cardiovascular Risk in Young Finns Study. Journal of Internal Medicine 2005 258 428-434.
30. Haarala A, Eklund C, Pessi T, Lehtimäki T, Huupponen R, Jula A, Viikari JSA, Raitakari O & Hurme M. Use of combined oral contraceptives alters metabolic determinants and genetic regulation of C-reactive protein. The Cardiovascular Risk in Young Finns Study. Scandinavian Journal of Clinical and Laboratory Investigation 2009 69 168-174.
31. Skouby SO, Gram J, Andersen LF, Sidelmann J, Petersen KR & Jespersen J. Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein concentrations. American Journal of Obstetrics and Gynecology 2002 186 969-977.
32. Wunder DM, Yared M, Bersinger NA, Widmer D, Kretschmer R & Birkhauser MH. Serum leptin and C-reactive protein levels in the physiological spontaneous menstrual cycle in reproductive age women. European Journal of Endocrinology 2006 155 137-142.
33. Schulze F, Maas R, Freese R, Schwedhelm E, Silberhorn E & Böger RH. Determination of a reference value for N(G), N(G)-dimethyl- L-arginine in 500 subjects. European Journal of Clinical Investigation 2005 35 622-626.
34. Teerlink T. HPLC analysis of ADMA and other methylated L-arginine analogs in biological fluids. Journal of Chromatography. B 2007 851 21-29.
35. Blackwell S, O'Reilly DS & Talwar D. Biological variation of asymmetric dimethylarginine and related arginine metabolites and analytical performance goals for their measurement in human plasma. European Journal of Clinical Investigation 2007 37 364-371.